Kane Biotech 2017 Year End and Fourth Quarter Financial Results and Business Update

Biotech Investing

Kane Biotech (TSXV:KNE) is pleased to announce its 2017 Year End and Fourth Quarter Financial Results. Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Biofilms are thin slimy films that develop when bacteria and other microorganisms form a protective matrix that …

Kane Biotech (TSXV:KNE) is pleased to announce its 2017 Year End and Fourth Quarter Financial Results. Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Biofilms are thin slimy films that develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack.

As quoted in the press release:

Over the past year Kane Biotech has focused the majority of its resources on applications of its technology on oral care and skin care in the companion pet market, human skin disorders, and the disinfection of hard surfaces.  Kane Biotech’s objective is to license the Company’s intellectual property to strategic partners with already established large scale market and territory access.

Click here to read the full press release.

The Conversation (0)
×